AU2008310732B2 - Novel sEH inhibitors and their use - Google Patents

Novel sEH inhibitors and their use Download PDF

Info

Publication number
AU2008310732B2
AU2008310732B2 AU2008310732A AU2008310732A AU2008310732B2 AU 2008310732 B2 AU2008310732 B2 AU 2008310732B2 AU 2008310732 A AU2008310732 A AU 2008310732A AU 2008310732 A AU2008310732 A AU 2008310732A AU 2008310732 B2 AU2008310732 B2 AU 2008310732B2
Authority
AU
Australia
Prior art keywords
methyl
trifluoromethyl
triazin
cis
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008310732A
Other languages
English (en)
Other versions
AU2008310732A1 (en
Inventor
Yun Ding
Joseph Paul Marino Jr.
Reema K. Thalji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2008310732A1 publication Critical patent/AU2008310732A1/en
Application granted granted Critical
Publication of AU2008310732B2 publication Critical patent/AU2008310732B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008310732A 2007-10-11 2008-10-10 Novel sEH inhibitors and their use Ceased AU2008310732B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97915407P 2007-10-11 2007-10-11
US60/979,154 2007-10-11
PCT/US2008/079517 WO2009049157A1 (en) 2007-10-11 2008-10-10 Novel seh inhibitors and their use

Publications (2)

Publication Number Publication Date
AU2008310732A1 AU2008310732A1 (en) 2009-04-16
AU2008310732B2 true AU2008310732B2 (en) 2012-03-08

Family

ID=40549589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008310732A Ceased AU2008310732B2 (en) 2007-10-11 2008-10-10 Novel sEH inhibitors and their use

Country Status (28)

Country Link
US (2) US8173805B2 (https=)
EP (1) EP2214487B1 (https=)
JP (1) JP5372943B2 (https=)
KR (1) KR101546111B1 (https=)
CN (1) CN101896065B (https=)
AU (1) AU2008310732B2 (https=)
BR (1) BRPI0817542A2 (https=)
CA (1) CA2702265C (https=)
CO (1) CO6270285A2 (https=)
CR (1) CR11423A (https=)
CY (1) CY1114865T1 (https=)
DK (1) DK2214487T3 (https=)
DO (1) DOP2010000101A (https=)
EA (1) EA018414B1 (https=)
ES (1) ES2445444T3 (https=)
HR (1) HRP20140105T1 (https=)
IL (1) IL204889A (https=)
MA (1) MA31761B1 (https=)
MX (1) MX2010003942A (https=)
MY (1) MY157116A (https=)
NZ (1) NZ584471A (https=)
PL (1) PL2214487T3 (https=)
PT (1) PT2214487E (https=)
RS (1) RS53180B (https=)
SI (1) SI2214487T1 (https=)
UA (1) UA107444C2 (https=)
WO (1) WO2009049157A1 (https=)
ZA (1) ZA201002465B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097378B1 (en) 2006-11-03 2012-09-12 GlaxoSmithKline LLC Novel seh inhibitors and their use
ES2404580T3 (es) 2007-10-11 2013-05-28 Glaxosmithkline Llc Novedosos inhibidores de la ehs y uso de los mismos
WO2009049157A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015104422A1 (en) 2014-01-13 2015-07-16 Basf Se Dihydrothiophene compounds for controlling invertebrate pests
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020074549A1 (en) * 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain
EP4618985A1 (en) 2022-11-18 2025-09-24 Universitat De Barcelona Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain
WO2026058000A2 (en) 2024-09-13 2026-03-19 Ucl Business Ltd Methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420283A (en) 1993-08-02 1995-05-30 Pfizer Inc. Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide
CA2348740A1 (en) 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
ES2385931T3 (es) 2000-07-07 2012-08-03 Spectrum Pharmaceuticals, Inc. MÉTODOS PARA EL TRATAMIENTO DE NEUROPATíA PERIFÉRICA INDUCIDA POR UNA ENFERMEDAD Y AFECCIONES RELACIONADAS.
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
WO2002058736A2 (en) 2000-12-12 2002-08-01 Neotherapetics, Inc. Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60222264T2 (de) 2001-06-29 2008-01-03 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Phenylpyrazolderivate als seh-inhibitoren
US20030055249A1 (en) 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
KR100875362B1 (ko) 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
BR0310061A (pt) 2002-05-16 2005-03-01 Pharmacia Corp Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
US20050197350A1 (en) 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
TW200519094A (en) 2003-07-02 2005-06-16 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
WO2005028467A1 (en) * 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
GB0401269D0 (en) 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
EP1794135A1 (en) 2004-09-27 2007-06-13 Amgen Inc. Substituted heterocyclic compounds and methods of use
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
JP2008523103A (ja) 2004-12-14 2008-07-03 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋプロテインキナーゼのピリミジンインヒビターおよびその使用
US20060276515A1 (en) 2005-05-06 2006-12-07 Cywin Charles L Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
JP2009511489A (ja) * 2005-10-07 2009-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益なｎ−置換ピリジノン又はピリミジノン化合物
CA2637620A1 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
EP2097378B1 (en) * 2006-11-03 2012-09-12 GlaxoSmithKline LLC Novel seh inhibitors and their use
US20100210655A1 (en) 2007-10-11 2010-08-19 Yun Ding NOVEL sEH INHIBITORS AND THEIR USE
ES2404580T3 (es) 2007-10-11 2013-05-28 Glaxosmithkline Llc Novedosos inhibidores de la ehs y uso de los mismos
WO2009049157A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
US8450843B2 (en) 2007-10-12 2013-05-28 Nec Corporation Semiconductor device and method for designing the same
WO2009070497A1 (en) 2007-11-28 2009-06-04 Smithkline Beecham Corporation SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE
EP2224928A4 (en) 2007-12-06 2012-02-15 Glaxosmithkline Llc NOVEL INHIBITORS OF SEH AND THEIR USE
US20100311776A1 (en) 2008-01-30 2010-12-09 Smithkline Beecham Corporation Novel sEH Inhibitors and their Use
JP2011510996A (ja) 2008-01-30 2011-04-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびその使用
WO2009097475A1 (en) 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
WO2010011917A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS

Also Published As

Publication number Publication date
EA018414B1 (ru) 2013-07-30
US8173805B2 (en) 2012-05-08
KR101546111B1 (ko) 2015-08-20
NZ584471A (en) 2012-01-12
CN101896065B (zh) 2013-12-18
JP5372943B2 (ja) 2013-12-18
MA31761B1 (fr) 2010-10-01
EA201070442A1 (ru) 2010-10-29
KR20100075619A (ko) 2010-07-02
DOP2010000101A (es) 2010-07-31
SI2214487T1 (sl) 2014-03-31
CN101896065A (zh) 2010-11-24
BRPI0817542A2 (pt) 2014-10-07
EP2214487B1 (en) 2013-11-27
HK1141211A1 (en) 2010-11-05
IL204889A0 (en) 2010-11-30
EP2214487A1 (en) 2010-08-11
EP2214487A4 (en) 2011-12-21
PT2214487E (pt) 2014-02-20
PL2214487T3 (pl) 2014-04-30
DK2214487T3 (da) 2014-02-10
MX2010003942A (es) 2010-04-30
JP2011500594A (ja) 2011-01-06
US20100249137A1 (en) 2010-09-30
CO6270285A2 (es) 2011-04-20
IL204889A (en) 2014-08-31
US20100210656A1 (en) 2010-08-19
RS53180B (sr) 2014-06-30
WO2009049157A1 (en) 2009-04-16
ES2445444T3 (es) 2014-03-03
MY157116A (en) 2016-05-13
HRP20140105T1 (hr) 2014-03-14
CA2702265C (en) 2014-12-02
AU2008310732A1 (en) 2009-04-16
US8212032B2 (en) 2012-07-03
CY1114865T1 (el) 2016-12-14
CR11423A (es) 2010-06-28
ZA201002465B (en) 2010-12-29
CA2702265A1 (en) 2009-04-16
UA107444C2 (uk) 2015-01-12

Similar Documents

Publication Publication Date Title
AU2008310732B2 (en) Novel sEH inhibitors and their use
US20100261743A1 (en) Novel seh inhibitors and their use
EP2217068A1 (en) NOVEL sEH INHIBITORS AND THEIR USE
EP2209376B1 (en) Novel seh inhibitors and their use
EP2097378B1 (en) Novel seh inhibitors and their use
US20100324076A1 (en) Novel sEH Inhibitors and their Use
EP2240025A1 (en) NOVEL sEH INHIBITORS AND THEIR USE
HK1141211B (en) Novel seh inhibitors and their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)